[Agnostics of immunological therapies in monotherapy and in association: impacts on clinical governance and on the patient's journey]

Recenti Prog Med. 2021 Dec;112(12):811-815. doi: 10.1701/3710.37006.
[Article in Italian]

Abstract

From "one-size-fits-all medicine" to stratified and precision medicine, to network oncology: the paradigm shift in therapeutic approaches in oncology is requiring new care and governance models. Molecular tumor board, network analysis, real-world evidence: only through new tools that do not reduce the complexity of the challenges will it be possible to introduce innovation into the healthcare system.

MeSH terms

  • Clinical Governance*
  • Delivery of Health Care
  • Humans
  • Immunotherapy
  • Medical Oncology
  • Neoplasms* / drug therapy
  • Precision Medicine